GP96 is over-expressed in oral cavity cancer and is a poor prognostic indicator for patients receiving radiotherapy

Chien Yu Lin, Ting Yang Lin, Hung Ming Wang, Shiang Fu Huang, Kang Hsing Fan, Chun Ta Liao, I. How Chen, Li Yu Lee, Yen Liang Li, Yin Ju Chen, Ann Joy Cheng, Joseph T. Chang

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Background: Oral cavity cancers (ORC) are the most common cancers, and standard treatment is radical surgery with postoperative radiotherapy. However, locoregional failure remains a major problem, indicating radioresistance an important issue. Our previous work has shown that GP96 contributed to radioresistance in nasopharyngeal and oral cancer cell lines. In this study, we determined clinical significance of GP96 in ORC by evaluation of GP96 expression and its association with disease prognosis in patients receiving radiotherapy. Methods: Total of 79 ORC patients (77 males, median age: 48 years old) receiving radical surgery and postoperative radiotherapy between Oct 1999 and Dec 2004 were enrolled. Patients in pathological stages II, III and IV were 16.5%, 16.5% and 67%, respectively. For each patient, a pair of carcinoma tissue and grossly adjacent normal mucosa was obtained. GP96-expression was examined by western blot analysis, and the association with clinicopathological status was determined.Results: Three-year locoregional control (LRC), distant metastasis-free survival (DMFS), disease-specific survival (DSS) and overall survival (OS) rates were 69%, 79%, 63% and 57%, respectively. We found that 55 patients (70%) displayed GP96-overexpression in the tumor tissue, which correlated with a higher pN stage (p = 0.020) and tumor depth (> 10 mm) (p = 0.045). Nodal extracapsular spreading (ECS) and GP96-overexpression predicted adverse LRC (p = 0.049 and p = 0.008). When stratified by nodal ECS, the adverse impact of GP96 remained significant in three-year LRC (p = 0.004). In multivariate analysis, GP96-overexpression was also an independent predictor of LRC, DSS and OS (p = 0.018, p = 0.011 and p = 0.012).Conclusion: GP96 may play roles in radioresistance which attributes to tumor invasiveness in oral cancer patients receiving radiotherapy. GP96 may serve as a novel prognostic marker of radiotherapy. However, further independent studies are required to validate our findings in a larger series.

Original languageEnglish
Article number136
JournalRadiation Oncology
Volume6
Issue number1
DOIs
Publication statusPublished - Oct 12 2011
Externally publishedYes

    Fingerprint

Keywords

  • Gp96
  • Oral cavity cancers
  • Prognosis
  • Radioresistance

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Medicine(all)

Cite this

Lin, C. Y., Lin, T. Y., Wang, H. M., Huang, S. F., Fan, K. H., Liao, C. T., Chen, I. H., Lee, L. Y., Li, Y. L., Chen, Y. J., Cheng, A. J., & Chang, J. T. (2011). GP96 is over-expressed in oral cavity cancer and is a poor prognostic indicator for patients receiving radiotherapy. Radiation Oncology, 6(1), [136]. https://doi.org/10.1186/1748-717X-6-136